Search
Centessa Pharmaceuticals PLC
CNTAAdd to Watchlist
40.020USD
+0.150+0.38%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
6.19BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Centessa Pharmaceuticals PLC is 7.00, ranking 316 out of 389 in the Biotechnology & Medical Research industry. The average price target is 36.00, with a high of 52.00 and a low of 30.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
43.571
Target Price
+8.87%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Centessa Pharmaceuticals PLC
CNTA
12
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Centessa Pharmaceuticals PLC's price target?
Analysts forecast that Centessa Pharmaceuticals PLC's price target is USD 36.00, with the highest forecast at USD 52.00 and the lowest forecast at USD 30.00.
How have Centessa Pharmaceuticals PLCCNTA's recent earnings per share performed?
The market expectation was USD -0.52, while Centessa Pharmaceuticals PLCCNTA's earnings per share (EPS) for the previous quarter was USD -0.47. EPS for the next quarter is expected at USD -0.41.
What is the analyst rating for Centessa Pharmaceuticals PLC?
Based on the ratings of Centessa Pharmaceuticals PLC's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
